Author Archives : Mohan Garikiparithi

Mohan Garikiparithi got his degree in medicine from Osmania University (University of Health Sciences). He practiced clinical medicine for over a decade before he shifted his focus to the field of health communications. During his active practice he served as the head of the Dept. of Microbiology in a diagnostic centre in India. On a three-year communications program in Germany, Mohan developed a keen interest in German Medicine (Homoeopathy), and other alternative systems of medicine. He now advocates treating different medical conditions without the use of traditional drugs. An ardent squash player, Mohan believes in the importance of fitness and wellness.

Advertisement

ReDO project finds common painkiller can fight against cancer

  The ReDO (Repurposing Drugs in Oncology) project is an international collaboration between the Anticancer Fund based in Belgium, and the US based GlobalCures. Their mission is to find untapped sources of novel treatments for cancer in existing and widely used non-cancer drugs. Their latest target is Diclofenac, a common painkiller. The ReDO researchers confirm ...click here to read more

‘Mid-life crisis’ theory challenged by University of Alberta study

A recent paper published in Developmental Psychology titled – Up, Not Down: The Age Curve in Happiness from Early Adulthood to Midlife – throws new light on the concept of “mid-life crisis.” The researchers who published this paper, Nancy Galambos, Harvey Krahn, Matt Johnson, based their findings on data drawn from two longitudinal studies by University ...click here to read more

Advertisement

Scientists searching for potential treatment for Parkinson’s in cholesterol-lowering drug

In a current clinical study, scientists are exploring the possibility of Simvastatin (a cholesterol lowering drug) being an effective method of treatment for people with Parkinson’s disease. They hope this cholesterol-lowering drug could join the growing list of effective treatments available for treating Parkinson’s disease. The study, which will take place in 21 centres in ...click here to read more

Advertisement